文献速递肺结节与肺癌

Plinabulin联合多西他赛对比多西他赛二线及以上治疗EGFR野生型非小细胞肺癌的3期随机试验(DUBLIN-3)

Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial.
PubMed 文献 · Lancet Respir Med · 2024-09-09

DUBLIN-3为国际多中心3期单盲平行随机对照试验,纳入一线铂类治疗后进展的EGFR野生型晚期非小细胞肺癌成人患者559例,随机接受多西他赛联合Plinabulin或多西他赛联合安慰剂。Plinabulin组3/4级腹泻、呕吐及一过性3级高血压更常见。

要点

  • Plinabulin联合多西他赛较单用多西他赛显著延长EGFR野生型NSCLC二/三线患者总生存期。
  • 联合方案需关注3/4级胃肠道反应及一过性3级高血压。
  • 该方案可考虑作为经铂类治疗后进展的EGFR野生型晚期NSCLC的新治疗选择。

核心结论

  • 在晚期或转移性EGFR野生型NSCLC经一线铂类治疗进展后,Plinabulin联合多西他赛作为二线和三线治疗显著改善总生存期,可考虑作为该人群的新治疗选择。

研究设计与样本

  • 国际多中心、3期、单盲、平行组、随机对照试验,在澳大利亚、中国和美国58个医疗中心入组患者。
  • 纳入EGFR野生型且一线铂类治疗后进展的成人NSCLC患者,按1:1随机分组,每21天为一周期,第1天静脉多西他赛75 mg/m2,第1天和第8天给予Plinabulin 30 mg/m2或安慰剂。
  • 共筛查919例,排除360例,入组并随机559例:Plinabulin组278例,对照组281例;安全性分析纳入至少接受一剂研究药物者。
  • 主要终点为意向治疗(ITT)人群的总生存期(OS)。

主要发现

  • Plinabulin组274例中273例(>99%)发生治疗中出现的不良事件,对照组278例中276例(99%)发生。
  • 3/4级胃肠道疾病在Plinabulin组更常见:腹泻24例(9%)vs 3例(1%),呕吐6例(2%)vs 1例(<1%);一过性3级高血压50例(18%)vs 8例(3%)。
  • 治疗中出现死亡在Plinabulin组12例(4%),对照组10例(4%)。

临床怎么用

  • 对一线铂类治疗后进展的EGFR野生型晚期或转移性NSCLC,可考虑多西他赛联合Plinabulin作为二线或三线治疗选项。
  • 治疗期间应重点监测腹泻、呕吐等胃肠道不良反应及血压,尤其警惕3级高血压。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is an unmet need for second-line and third-line treatments that are effective and tolerable for advanced or metastatic non-small-cell lung cancer (NSCLC) with no driver mutations. METHODS: In this phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial, we enrolled patients from 58 medical centres in Australia, China, and the USA. Eligible patients were adults with epidermal growth factor receptor (EGFR) wild-type NSCLC who had progressed after first-line platinum-based therapy. Patients were randomly assigned (1:1) using an independent stratified randomisation schedule with a block size of four to receive intravenous docetaxel 75 mg/m2 on day 1 and either plinabulin (30 mg/m2) or placebo on days 1 and 8 in 21-day cycles until progression, unacceptable toxic effects, withdrawal, or death. The primary endpoint was overall survival (OS) in the intention-to-treat (ITT) population. Safety was analysed in all patients who had received at least one dose of study drug or placebo. This trial is registered with ClinicalTrials.gov (NCT02504489) and is now closed. FINDINGS: Between Nov 30, 2015, and Jan 6, 2021, 919 patients were screened for inclusion. 360 patients were excluded, and 559 were enrolled and randomly assigned to receive either docetaxel and plinabulin (n=278) or docetaxel and placebo (n=281). 406 (73%) of 559 patients were male, 153 (27%) were female, and 488 (87%) were Asian. Median OS was 10·5 months (95% CI 9·34-11·87) in the plinabulin group compared with 9·4 months (8·38-10·68) in the control group (stratified HR 0·82, 95% CI 0·68-0·99; p=0·0399). Mean OS was 15·08 months (13·42-16·74) in the plinabulin group compared with 12·77 months (11·45-14·10) in the placebo group using restricted mean survival time analysis (difference 2·31 months, 95% CI 0·18-4·44; p=0·0332). Treatment-emergent adverse events occurred in 273 (>99%) of 274 patients in the plinabulin group and 276 (99%) of 278 patients in the control group. Grade 3 or 4 gastrointestinal disorders occurred more frequently in the plinabulin group than in the placebo group, with the most frequent being diarrhoea (24 [9%] of 274 patients vs three [1%] of 278) and vomiting (six [2%] vs one [<1%]), as did transient grade 3 hypertension (50 [18%] vs eight [3%]). Treatment-emergent death was reported in 12 patients (4%) in the plinabulin group and ten patients (4%) in the placebo group. INTERPRETATION: Plinabulin plus docetaxel significantly improved OS as second-line and third-line treatment in patients with advanced or metastatic EGFR wild-type NSCLC and could be considered as a new treatment option in this population. FUNDING: BeyondSpring Pharmaceuticals.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Han B, Feinstein T, Shi Y, et al. Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respir Med. 2024. PMID: 39265599. doi:10.1016/S2213-2600(24)00178-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。